DEVELOPMENT OF NOVEL TETRACYCLINE COUNTERMEASURES FOR RESPIRATORY DISEASES

呼吸系统疾病新型四环素对策的开发

• 批准号: 8882790
• 负责人: Anne Kathleen Radcliff
• 金额: $ 302.4万
• 依托单位: CUBRC, INC.
• 依托单位国家: 美国
• 财政年份: 2011
• 资助国家: 美国
• 起止时间: 2011-09-30 至 2016-09-29
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8882790
• 关键词: Advanced Development; Anti-Bacterial Agents; Antimicrobial Resistance; Bacillus anthracis; Clinical; Development; Drug resistance; Lung diseases; Respiratory Tract Infections; Support Contracts; Tetracyclines; Therapeutic; Translational Research; biodefense; novel; pathogen; pre-clinical; product development; research and development

This contract supports the advanced development of promising biodefense therapeutic candidates/products with broad spectrum activity. The research and development activities supported will allow candidate therapeutic countermeasures to progress through the product development pipeline, and includes preclinical/non-clinical and clinical IND development activities.

该合同支持具有广谱活性的有前景的生物防御治疗候选/产品的高级开发。所支持的研究和开发活动将允许候选治疗对策在产品开发管道中取得进展，包括临床前/非临床和临床IND开发活动。